New cancer injection enters first human trials
NCT ID NCT06985368
Summary
This is an early-stage study to test the safety and dosing of a new drug called SIBP-A18 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to up to 156 participants to find the safest maximum dose and look for early signs that the drug might help shrink tumors. The study focuses on safety first, while also gathering initial information about how the drug works in the body and its potential effects on cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.